We earn commissions from the providers listed here. No provider buys a position, a rating, or a listing. The order is set by hand, and we do not claim it is independent of what we earn. Advertising Disclosure

Zepbound vs Wegovy: The Weight-Loss Injectable Comparison

Zepbound (tirzepatide) produced more weight loss than Wegovy (semaglutide) in the head-to-head trial. Compare results, side effects, coverage, and self-pay pricing.

Key Takeaways

Zepbound (tirzepatide) and Wegovy (semaglutide) are the two FDA-approved weight-loss injectables, and Zepbound produces more weight loss: 20.2% versus 13.7% average body weight loss in the head-to-head SURMOUNT-5 trial at 72 weeks (individual results vary). Wegovy counters with published cardiovascular outcomes data (20% reduction in heart events) and a self-pay price of $349-$399 per month versus Zepbound $299-$449 vials with an on-time refill (up to $699 if it lapses). Zepbound also treats sleep apnea. Choose by insurance coverage first, then by whether maximum weight loss or heart protection matters more.

Zepbound vs Wegovy at a Glance

FeatureZepboundWegovy
Active ingredientTirzepatide (GIP + GLP-1)Semaglutide (GLP-1)
Diabetes siblingMounjaroOzempic
Head-to-head weight loss (SURMOUNT-5)20.2% at 72 weeks13.7% at 72 weeks
Cardiovascular outcome dataNot yet published for weight populationYes (SELECT: 20% MACE reduction)
Additional FDA approvalObstructive sleep apnea (Dec 2024)Cardiovascular risk reduction
Self-pay priceLillyDirect vials $299-$449/month (on-time refill; up to $699 if lapsed)NovoCare $349-$399/month ($199 intro)
Retail list price~$1,086/month~$1,350/month
Insurance (covered) copayAs low as $25/monthAs low as $25/month

About This Comparison

Our Editorial Standards

This weight loss provider comparison is independently researched by our editorial team. We compare telehealth services based on publicly available information including pricing, available treatments, and service areas. Our ratings are editorial judgments, not tallies of reviews.

Independent Research: We do not accept payment for rankings or favorable reviews
Affiliate Disclosure: We may earn commissions from qualifying purchases at no extra cost to you
Regular Updates: Content is reviewed and updated monthly for accuracy
Licensed Providers Only: All listed services employ US-licensed healthcare providers

Not Medical Advice: This comparison is for informational purposes only. We are not healthcare providers. Always consult with a licensed physician before starting any treatment. Read our full medical disclaimer and editorial policy.

Independent ResearchNo paid placements
Fact-Checked InformationVerified against official sources
Regularly UpdatedContent reviewed monthly
Licensed Providers OnlyAll listed services are US-licensed

Zepbound vs Wegovy: The Weight-Loss Injectable Comparison

Eric GoldWritten by Eric GoldEditor-in-Chief
10 min read

Zepbound and Wegovy are the two branded injectables the FDA has approved specifically for chronic weight management, and they are the weight-labeled siblings of the diabetes drugs Mounjaro and Ozempic. Zepbound is tirzepatide, a dual GIP and GLP-1 agonist; Wegovy is semaglutide, a GLP-1 agonist. The head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine, settled the effectiveness question directly: Zepbound produced 20.2% average body weight loss versus Wegovy 13.7% at 72 weeks. But effectiveness is only one axis. Wegovy holds published cardiovascular outcomes data from the SELECT trial that Zepbound has not yet matched, runs a competitive self-pay price through NovoCare, and both differ in their secondary approvals and coverage patterns. This comparison covers the trial results, the safety and coverage differences, and the real 2026 pricing, so you can weigh maximum weight loss against heart-protection evidence and cost.

Effectiveness: Zepbound Leads

The SURMOUNT-5 head-to-head trial gave a clear answer on weight loss: Zepbound produced 20.2% average body weight reduction against Wegovy 13.7% over 72 weeks, tested in the same patients under the same conditions. That roughly 6.5-point gap translates to about 15 extra pounds for a 240-pound starting weight, and more Zepbound patients reached the deeper 15% and 20% loss thresholds. The dual-hormone mechanism, adding GIP to the GLP-1 action both drugs share, is the leading explanation for the edge.
The usual caveats apply: these are averages hiding wide individual spread, strong Wegovy responders beat weak Zepbound responders, and roughly one in six patients on either drug loses less than 5%. No test predicts your personal response, so your own results at three months matter more than the trial average. But as a population statement, Zepbound is the more effective weight-loss drug, and that is the single strongest argument in its favor.

Where Wegovy Counters: Heart Data and Price

Wegovy holds two meaningful advantages. First, cardiovascular outcomes: the SELECT trial found semaglutide reduced major adverse cardiac events by 20% in people with obesity and existing cardiovascular disease, published evidence that Zepbound has not yet produced for the weight-loss population. For patients whose primary concern is heart protection, not just the number on the scale, that established data tilts the choice toward Wegovy.
Second, self-pay price: Wegovy now runs $349 per month for standard doses and $399 for the 7.2mg high dose through the NovoCare Pharmacy direct channel (as low as $199 with the introductory rate through December 31, 2026), while Zepbound through LillyDirect vials starts lower at $299 for the 2.5mg dose but climbs to $449 at 7.5mg and up with an on-time refill within 45 days, or $499-$699 if that refill lapses. At the starting dose Zepbound is the cheaper option; at maintenance doses taken on time the two run close, with Wegovy $399 ceiling edging under Zepbound $449; miss a Zepbound refill window and Wegovy becomes the clearly cheaper option. Zepbound has its own counter here, the December 2024 obstructive sleep apnea approval, which opens insurance coverage pathways (including potential Medicare) that Wegovy weight-only label does not, for patients with diagnosed OSA.

Shared Side Effects and Considerations

Both drugs share the GLP-1 class gastrointestinal profile, since both slow stomach emptying: nausea, vomiting, diarrhea, and constipation, concentrated during dose escalation and easing with adaptation. In SURMOUNT-5, side-effect rates were broadly similar between the two despite Zepbound greater weight loss. The serious-but-rare risks are identical: pancreatitis, gallbladder disease that rapid weight loss itself promotes, and the thyroid C-cell tumor warning excluding people with personal or family history of medullary thyroid carcinoma. Neither is used in pregnancy.
The shared realities of GLP-1 weight loss apply to both: muscle loss accompanies rapid fat loss, making protein intake and resistance training essential regardless of which drug you take, and weight regain after stopping is well documented for both, so the honest planning horizon is multi-year maintenance rather than a finite course. These shared factors mean the choice between Zepbound and Wegovy is genuinely about the effectiveness-versus-heart-data-versus-price tradeoff, not about meaningfully different safety or tolerability.

Which Should You Choose?

Insurance decides first. If your plan covers one and not the other, take the covered drug, because a 6.5-point average efficacy difference does not justify thousands of dollars per year out of pocket when a covered alternative exists, and covered patients pay as little as $25 per month for either. Check your formulary before anything else.
Self-pay and choosing freely, weigh three things. For maximum weight loss, Zepbound is the evidence-backed choice if the $299-$449 monthly cost (on-time refill; up to $699 if a refill lapses) fits. For heart protection with existing cardiovascular disease, Wegovy published SELECT data and its $349-$399 self-pay price (as low as $199 with the current introductory rate) make it the stronger option. For diagnosed obstructive sleep apnea, Zepbound OSA approval opens coverage Wegovy cannot access. And if the branded prices are simply out of reach, compounded semaglutide from $99 to $299 per month (not FDA-approved) delivers most of Wegovy benefit at a fraction of the cost, which our compounded semaglutide cost guide covers in detail. Switching between the two is routine if your first choice stalls or is poorly tolerated.

Frequently Asked Questions

Is Zepbound more effective than Wegovy?

Yes, on weight loss, and the evidence is direct. The SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine tested both drugs in the same patients under identical conditions for 72 weeks and found Zepbound (tirzepatide) produced 20.2% average body weight loss versus Wegovy (semaglutide) 13.7%, a roughly 6.5-point gap that means about 15 extra pounds for a 240-pound starting weight, with more Zepbound patients hitting the deeper 15% and 20% thresholds. The dual-hormone mechanism, adding GIP to the GLP-1 action, drives the difference. Two honest qualifiers: averages hide wide individual variation, so a strong Wegovy responder can outperform a weak Zepbound responder, and Wegovy holds one advantage Zepbound does not, published cardiovascular outcomes data showing a 20% reduction in heart events in the SELECT trial. So Zepbound is more effective for weight loss specifically, but Wegovy may be the better choice for someone whose primary concern is documented heart protection, and both are far more effective than any pre-2021 weight-loss medication.

Which is cheaper, Zepbound or Wegovy?

It depends on dose and refill timing. Wegovy costs $349 per month for standard doses and $399 for the 7.2mg high dose through the NovoCare Pharmacy direct channel (as low as $199 with the current introductory rate through December 31, 2026). Zepbound through LillyDirect vials starts lower at $299 for the 2.5mg starting dose, rising to $449 at 7.5mg and up as long as you refill within 45 days of your last delivery; miss that window and the higher doses jump to $499-$699. At the starting dose Zepbound is cheaper; at maintenance doses taken on time the two run close, with Wegovy edging slightly under Zepbound; and if a Zepbound refill lapses, Wegovy becomes clearly the cheaper option. Retail list prices favor Zepbound slightly ($1,086 versus $1,350), but almost nobody should pay retail given the direct channels. With insurance coverage, the comparison collapses: if you are covered, a manufacturer savings card brings either drug to as little as $25 per month, which is why checking your formulary matters more than comparing self-pay prices. And if branded pricing is out of reach entirely, compounded semaglutide (the same molecule as Wegovy, though not FDA-approved and not reviewed by the FDA for safety, effectiveness, or quality) runs $99 to $299 per month through the telehealth programs we track, the budget lane Zepbound lacks since compounded tirzepatide lost its legal basis in 2025. HSA and FSA funds apply to all legitimate routes. Branded figures as of August 2026; confirm current pricing at checkout, since manufacturer self-pay programs change without notice.

What is the difference between Zepbound and Wegovy besides the drug?

Beyond the active ingredients (tirzepatide in Zepbound, semaglutide in Wegovy), the meaningful differences are their evidence bases, secondary approvals, and pricing. Effectiveness: Zepbound produced more weight loss head-to-head (20.2% versus 13.7%). Heart data: Wegovy has published cardiovascular outcomes showing a 20% reduction in major cardiac events (the SELECT trial), which Zepbound has not yet matched for the weight-loss population. Secondary approval: Zepbound gained an obstructive sleep apnea indication in December 2024 that opens coverage pathways for OSA patients, while Wegovy carries a cardiovascular risk-reduction indication reflecting its SELECT data. Price: Wegovy runs $349-$399 through NovoCare (as low as $199 with the current introductory rate); Zepbound vials run $299-$449 by dose with an on-time refill, or up to $699 if a refill lapses. Both share the same GLP-1 side-effect profile, the same serious-but-rare risks, and the same weight-regain-after-stopping reality. Their diabetes siblings differ too, Wegovy pairs with Ozempic, Zepbound with Mounjaro, which matters if your diagnosis is diabetes rather than obesity. The practical decision comes down to insurance coverage first, then whether maximum weight loss, heart protection, or sleep apnea treatment is your priority.

Can I switch from Wegovy to Zepbound or vice versa?

Yes, switching between the two is common and clinically routine, most often from Wegovy to Zepbound when a patient plateaus or wants the greater weight loss the head-to-head data supports, though the reverse also happens over cost, insurance changes, or a desire for Wegovy heart-protection data. Providers typically transition directly, starting the new drug at a low-to-mid dose rather than the very bottom of its titration ladder, adjusted for how much of the previous drug you were taking, and there is no required washout period, though your provider will time the first new dose against your last previous injection. Set realistic expectations: switching helps many plateaued or non-responding patients, but it is not guaranteed, since some of a plateau reflects physiology common to both drugs and to weight loss generally. Because the two titration schedules do not map one-to-one, this is a prescriber-managed change, not a self-directed swap. If cost rather than effectiveness drives your switch, also consider that compounded semaglutide offers the Wegovy molecule at $99 to $299 per month, which may solve the budget problem without changing the underlying medication; compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.

Do Zepbound and Wegovy have the same side effects?

Largely yes, because both act on the GLP-1 pathway that slows stomach emptying. The gastrointestinal profile is shared: nausea most commonly, then vomiting, diarrhea, and constipation, concentrated during the dose-escalation weeks and easing as your body adapts. In the SURMOUNT-5 head-to-head, side-effect rates were broadly similar between the two despite Zepbound producing substantially more weight loss, which some read as mildly favorable for Zepbound tolerability relative to its effect. The serious-but-rare risks are identical: pancreatitis, gallbladder disease that rapid weight loss itself can trigger, and the thyroid C-cell tumor warning that excludes anyone with personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Neither is used in pregnancy. Both also share the non-drug realities of rapid weight loss: muscle loss that makes protein intake and resistance training important, and weight regain after discontinuation that makes maintenance planning essential. Management is the same for both: slow titration, smaller and lower-fat meals during escalation, hydration, and working with your prescriber on dose adjustments rather than quitting when side effects appear.

Sources & References

Our comparisons are informed by official sources and regulatory guidelines. We encourage readers to verify information with authoritative sources.

Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards

Ready to Compare Providers?

See which telehealth providers carry these treatments, at what price, and get started today.

Compare Weight Loss ProvidersEstimate Your Cost

Related Resources

Article

Best Weight Loss Providers

Weight Loss
Article

Treatment Cost Calculator

Medical Disclaimer: This comparison is for informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication. Individual results and experiences may vary. Read our full medical disclaimer.